Immunologically, IFN-γ extends to both tumor cells (through MHC-I upregulation) and immune cells (via macrophage activation and dendritic cell cross-presentation), working synergistically to promote CD8+ T cell antigen recognition (Garris et al., 2018[34]). The gene discussed is CD8A; the disease is neoplasm.